Amyloid-ß peptide-induced cytotoxicity and mitochondrial dysfunction in yeast

FEMS Yeast Research

Volumn 15, Issue 6, 2015, Pages

  Chen, Xin ^a   Petranovic, Dina ^a  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Alzheimer's disease; Amyloid ; Mitochondria; Oxidative stress; Ubiquitin proteasome system; yeast

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; PROTEASOME; REACTIVE OXYGEN METABOLITE; SIGNAL PEPTIDE; UBIQUITIN;

ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL MODEL; CELL DAMAGE; CELL DEATH; CELL DYSFUNCTION; CELL STRESS; CONTROLLED STUDY; CYTOPATHOLOGY; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME REPRESSION; FUNGAL BIOMASS; FUNGUS GROWTH; GROWTH RATE; MITOCHONDRIAL RESPIRATION; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SACCHAROMYCES CEREVISIAE; BIOSYNTHESIS; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; PROTEIN DEGRADATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEOLYSIS; SACCHAROMYCES CEREVISIAE;

EID: 84982279870     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1093/femsyr/fov061     Document Type: Article

References (52)

1. Aleardi AM, Benard G, Augereau O, et al. Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bioenerg Biomembr 2005;37:207-25.
2. Bagriantsev S, Liebman S. Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. BMC Biol 2006;4:32.
3. Bharadwaj P, Waddington L, Varghese J, et al. A new method to measure cellular toxicity of non-fibrillar and fibrillar Alzheimer's A beta using yeast. J Alzheimers Dis 2008;13:147-50.
4. Braun RJ, Buttner S, Ring J, et al. Nervous yeast: modeling neurotoxic cell death. Trends Biochem Sci 2010;35:135-44.
5. Braun RJ, Sommer C, Leibiger C, et al. Accumulation of basic amino acids at mitochondria dictates the cytotoxicity of aberrant ubiquitin. Cell Rep 2015;10:1557-71.
6. Caine J, Sankovich S, Antony H, et al. Alzheimer's A beta fused to green fluorescent protein induces growth stress and a heat shock response. FEMS Yeast Res 2007;7:1230-6.
7. Calkins MJ, Manczak M, Mao PZ, et al. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degenerationin a mouse model of Alzheimer's disease. Hum Mol Genet 2011;20:4515-29.
8. Caspersen C, Wang N, Yao J, et al. Mitochondrial A beta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 2005;19:2040-1.
9. Chen Y, Daviet L, Schalk M, et al. Establishing a platform cell factory through engineering of yeast acetyl-CoA metabolism. Metab Eng 2013;15:48-54.
10. Crouch PJ, Harding S-ME, White AR, et al. Mechanisms of Aß mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell B 2008;40:181-98.
11. Crowther DC, Kinghorn KJ, Miranda E, et al. Intraneuronal Aß, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 2005;132:123-35.
12. D'Angelo F, Vignaud H, Di Martino J, et al. A yeast model for amyloid-ß aggregation exemplifies the role of membrane trafficking and PICALM in cytotoxicity. Dis Model Mech 2013;6:206-16.
13. Fabrizio P, Longo VD. The chronological life span of Saccharomyces cerevisiae. Aging Cell 2003;2:73-81.
14. Ferri CP, PrinceM, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7.
15. Fukui H, Moraes CT. The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis? Trends Neurosci 2008;31: 251-6.
16. Gouras GK, Tsai J, Naslund J, et al. Intraneuronal Aß42 accumulation in human brain. Am J Pathol 2000;156:15-20.
17. Hardy J, Selkoe DJ. Medicine-the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
18. Hartley DM, Walsh DM, Ye CPP, et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999;19:8876-84.
19. Khurana V, Lindquist S. Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? Nat Rev Neurosci 2010;11:436-49.
20. Knobloch M, Konietzko U, Krebs DC, et al. Intracellular Aß and cognitive deficits precede ß-amyloid deposition in transgenic arcAß mice. Neurobiol Aging 2007;28:1297-306.
21. Komano H, Seeger M, Gandy S, et al. Involvement of cell surface glycosyl-phosphatidylinositol-linked aspartyl proteases in alpha-secretase-type cleavage and ectodomain solubilization of human Alzheimer beta-amyloid precursor protein in yeast. J Biol Chem 1998;273:31648-51.
22. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007;8:499-509.
23. Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. P Natl Acad Sci USA 1995;92:9368-72.
24. Livnat-Levanon N, Kevei E, Kleifeld O, et al. Reversible 26S proteasome disassembly upon mitochondrial stress. Cell Rep 2014;7:1371-80.
25. Luheshi LM, Tartaglia GG, Brorsson AC, et al. Systematic in vivo analysis of the intrinsic determinants of amyloid beta pathogenicity. PLoS Biol 2007;5:2493-500.
26. Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links A beta to mitochondrial toxicity in Alzheimer's disease. Science 2004;304:448-52.
27. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Aß amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-6.
28. Macreadie I, Lotfi-MiriM, Mohotti S, et al. Validation of folate in a convenient yeast assay suited for identification of inhibitors of Alzheimer's amyloid-beta Aggregation. J Alzheimers Dis 2008;15:391-6.
29. Macreadie IG, Castelli LA, Hewish DR, et al. A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects. P Natl Acad Sci USA 1995;92: 2770-4.
30. Magrane J, Smith RC, Walsh K, et al. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci 2004;24: 1700-6.
31. Maharjan S, Oku M, Tsuda M, et al. Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition. Sci Rep 2014;4:11.
32. Manczak M, Mao P, Calkins M, et al. Mitochondriatargeted antioxidants protect against Abeta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 2010;20: S609-S31.
33. Matlack KES, TardiffDF, Narayan P, et al. Clioquinol promotes the degradation of metal-dependentamyloid-ß (Aß) oligomers to restore endocytosis and ameliorate Aß toxicity. P Natl Acad Sci USA 2014;111:4013-8.
34. Matsumoto K, Akao Y, Yi H, et al. Overexpression of amyloid precursor protein induces susceptibility to oxidative stress in human neuroblastoma SH-SY5Y cells. J Neural Transm 2006;113:125-35.
35. Mirisola MG, Braun RJ, Petranovic D. Approaches to study yeast cell aging and death. FEMS Yeast Res 2014;14: 109-18.
36. Mossmann D, Vögtle FN, Taskin Asli A, et al. Amyloid-ß peptide induces mitochondrial dysfunction by inhibition of preprotein maturation. Cell Metab 2014;20:662-9.
37. Mumberg D, Muller R, Funk M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene 1995;156:119-22.
38. Munoz AJ, Wanichthanarak K, Meza E, et al. Systems biology of yeast cell death. FEMS Yeast Res 2012;12: 249-65.
39. Petersen CAH, Alikhani N, Behbahani H, et al. The amyloid betapeptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. P Natl Acad Sci USA 2008;105:13145-50.
40. Petranovic D, Nielsen J. Can yeast systems biology contribute to the understanding of human disease? Trends Biotechnol 2008;26:584-90.
41. Segref A, Kevei E, Pokrzywa W, et al. Pathogenesis of human mitochondrial diseases is modulated by reduced activity of the ubiquitin/proteasome system. Cell Metab 2014;19: 642-52.
42. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66.
43. Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell 2007;131:215-21
44. Shahul H, Ging-Yuek RH. The role of mitochondria in aging, neurodegenerative disease, and future therapeutic options. B C Med J 2011;53:188-92.
45. Takahashi RH, Milner TA, Li F, et al. Intraneuronal Alzheimer Aß42 Accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 2002;161: 1869-79.
46. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008;283:29615-9.
47. Treusch S, Hamamichi S, Goodman JL, et al. Functional links between Aß toxicity, endocytic trafficking and Alzheimer's disease risk factors in yeast. Science 2011;334: 1241-5.
48. Tyo KEJ, Liu ZH, Magnusson Y, et al. Impact of protein uptake and degradation on recombinant protein secretion in yeast. Appl Microbiol Biot 2014;98:7149-59.
49. Williams M. Progress in Alzheimer's disease drug discovery: an update. Curr Opin Invest Dr 2009;10:23-34.
50. Winderickx J, Delay C, DeVos A, et al. Protein folding diseases and neurodegeneration: lessons learned from yeast. BBA-Mol Cell Res 2008;1783:1381-95.
51. Yao J, Irwin RW, Zhao LQ, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. P Natl Acad Sci USA 2009;106:14670-5.
52. Zhang W, Espinoza D, Hines V, et al. Characterization of betaamyloid peptide precursor processing by the yeast Yap3 and Mkc7 proteases. BBA-Mol Cell Res 1997;1359:110-22.